Titre
Decrease in the prevalence of hepatitis B and a low prevalence of hepatitis C virus infections in the general population of the Seychelles.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Bovet, P.
Auteure/Auteur
Yersin, C.
Auteure/Auteur
Herminie, P.
Auteure/Auteur
Lavanchy, D.
Auteure/Auteur
Frei, P.C.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
0042-9686
Statut éditorial
Publié
Date de publication
1999
Volume
77
Numéro
11
Première page
923
Dernière page/numéro d’article
928
Peer-reviewed
Oui
Langue
anglais
Notes
http://www.who.int/bulletin/archives/77(11)923.pdf
Résumé
A serological survey of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections was carried out on a random sex- and age-stratified sample of 1006 individuals aged 25-64 years in the Seychelles islands. Anti-HBc and anti-HCV antibodies were detected using commercially available enzyme-linked immunosorbent assays (ELISA), followed by a Western blot assay in the case of a positive result for anti-HCV. The age-adjusted seroprevalence of anti-HBc antibodies was 8.0% (95% CI: 6.5-9.9%) and the percentage prevalence among males/females increased from 7.0/3.1 to 19.1/13.4 in the age groups 25-34 to 55-64 years, respectively. Two men and three women were positive for anti-HCV antibodies, with an age-adjusted seroprevalence of 0.34% (95% CI: 0.1-0.8%). Two out of these five subjects who were positive for anti-HCV also had anti-HBc antibodies. The seroprevalence of anti-HBc was significantly higher in unskilled workers, persons with low education, and heavy drinkers. The age-specific seroprevalence of anti-HBc in this population-based survey, which was conducted in 1994, was approximately three times lower than in a previous patient-based survey carried out in 1979. Although there are methodological differences between the two surveys, it is likely that the substantial decrease in anti-HBc prevalence during the last 15 years may be due to significant socioeconomic development and the systematic screening of blood donors since 1981. Because hepatitis C virus infections are serious and the cost of treatment is high, the fact that the prevalence of anti-HCV antibodies is at present low should not be an argument for not screening blood donors for anti-HCV and eliminating those who are positive.
Sujets
PID Serval
serval:BIB_904884A01CC2
PMID
Date de création
2011-09-02T17:14:43.424Z
Date de création dans IRIS
2025-05-20T22:32:46Z